Acute Lung Injury - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury - Pipeline Review, H2 2016, provides an overview of the Acute Lung Injury (Respiratory) pipeline landscape.

Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lung Injury - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lung Injury (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lung Injury (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively.

Acute Lung Injury (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lung Injury (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Lung Injury (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lung Injury (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lung Injury (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lung Injury (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lung Injury (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lung Injury (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Lung Injury Overview 10
Therapeutics Development 11
Pipeline Products for Acute Lung Injury - Overview 11
Pipeline Products for Acute Lung Injury - Comparative Analysis 12
Acute Lung Injury - Therapeutics under Development by Companies 13
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15
Acute Lung Injury - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Acute Lung Injury - Products under Development by Companies 19
Acute Lung Injury - Products under Investigation by Universities/Institutes 21
Acute Lung Injury - Companies Involved in Therapeutics Development 22
Altor BioScience Corp 22
Asklepion Pharmaceuticals LLC 23
Commence Bio Inc 24
CompleGen Inc 25
GlaxoSmithKline Plc 26
Histocell SL 27
Lung Therapeutics Inc 28
Navigen Pharmaceuticals Inc 29
Quark Pharmaceuticals Inc 30
S-Evans Biosciences Inc 31
Silence Therapeutics Plc 32
Stemedica Cell Technologies Inc 33
Acute Lung Injury - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ALT-836 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Atu-111 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
BC-1215 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BIO-10901 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
CGX-1037 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CMB-200 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
EC-18 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
FAB-117HC - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
GSK-2586881 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
GSK-2862277 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
L-Citrulline - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
LTI-02 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
MG-53 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
NAV-2729 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
P- BEFizumab - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
QPLI-2 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
R-10001 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
R-107 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
R-901 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
R-911 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Recombinant Proteins for Acute Lung Injury - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
S-1229 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Stem Cell Therapy for Acute Lung Injury - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
TXA-302 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Acute Lung Injury - Dormant Projects 89
Acute Lung Injury - Discontinued Products 92
Acute Lung Injury - Product Development Milestones 93
Featured News & Press Releases 93
Mar 03, 2015: Navigen Announces Phase I NIH SBIR Award to support the Development of ARF6 Inhibitors to Treat Acute Lung Injury/Acute Respiratory Distress 93
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 93
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 94
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 94
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables

Number of Products under Development for Acute Lung Injury, H2 2016 11
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Acute Lung Injury - Pipeline by Altor BioScience Corp, H2 2016 22
Acute Lung Injury - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 23
Acute Lung Injury - Pipeline by Commence Bio Inc, H2 2016 24
Acute Lung Injury - Pipeline by CompleGen Inc, H2 2016 25
Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2016 26
Acute Lung Injury - Pipeline by Histocell SL, H2 2016 27
Acute Lung Injury - Pipeline by Lung Therapeutics Inc, H2 2016 28
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals Inc, H2 2016 29
Acute Lung Injury - Pipeline by Quark Pharmaceuticals Inc, H2 2016 30
Acute Lung Injury - Pipeline by S-Evans Biosciences Inc, H2 2016 31
Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2016 32
Acute Lung Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Number of Products by Stage and Target, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 38
Number of Products by Stage and Route of Administration, H2 2016 40
Number of Products by Stage and Molecule Type, H2 2016 42
Acute Lung Injury - Dormant Projects, H2 2016 89
Acute Lung Injury - Dormant Projects (Contd..1), H2 2016 90
Acute Lung Injury - Dormant Projects (Contd..2), H2 2016 91
Acute Lung Injury - Discontinued Products, H2 2016 92